North of Tyne Area Prescribing Committee Agenda

North of Tyne
Area Prescribing Committee
(www.northoftyneapc.nhs.uk)
Tuesday 10th January 2012.
Room 1, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt Business Park.
The meeting will start at 12:30pm

AGENDA

1.  / Apologies for absence
2.  / Minutes and decision summary from the meeting held on Tuesday 8th November 2011 / e-mail sent 28/11/11
3.  / Matters arising/actions from previous meeting
·  Dabigatran (2011/55)
·  Tapentadol –notification of intent to appeal
·  Dressings formulary (2011/74)
4.  / Appeals against previous decisions
·  No appeals to be heard
5.  / Report from the Formulary sub-group
·  Formulary version 3.4 November 2011
·  Minutes and recommendations from meeting held on 15th December
o  Boceprevir / Available on website
e-mail sent 4/1/12
Paper to follow
6.  / Report from the Shared Care Group
·  Retigabine information sheet – final draft
·  Minutes from meeting on 14/12/2011 / e-mail sent 5/12/11
e-mail sent 6/1/12
7.  / COPD treatment review / Paper to follow
8.  / Appliance Formulary
9.  / Report from the Antimicrobial Chemotherapy Sub-group
·  None received
10. / Report from Medicines Management QIPP Sub-group
·  Draft minutes from meeting held on 21/9/11
·  Draft minutes from meeting held on 14/12/11 / e-mail sent 21/11/11
e-mail sent 4/1/12
11. / Documents previously circulated by e-mail
·  NECDAG Decision summary - Lenalidomide (Revlimid) for Myelodysplastic syndrome with the 5q minus cytogenetic abnormality
·  NECDAG Decision summary - Degarelix (Firmagon) for first line treatment of advanced hormone-dependent prostate cancer at with a PSA > 20ng/l at presentation.
·  NECDAG Decision summary - FOLFIRINOX Management of selected patients with inoperable pancreatic cancer (First line for inoperable pancreatic cancer in patients with performance status 0-1.)
·  NECDAG Decision summary- Gemcitabine and Capecitabine for management of advanced pancreatic cancer.
·  NECDAG Cancer Drug Fund Decision – Imatinib: Adjuvant treatment of adult patients who are at significant risk of relapse following resection of GIST
·  NECDAG Cancer Drug Fund Decision – Abiraterone in combination with prednisolone for the treatment of metastatic castration resistant prostate cancer which has progressed on or after a docetaxel-based chemotherapy regimen
·  NECDAG Cancer Drug Fund Decision - Ipilimumab 2nd line treatment of Metastatic melanoma
·  NECDAG Cancer Drug Fund Decision - Bevacizumab in combination with Capecitabine in metastatic breast cancer.
·  NECDAG Gateway Decision – Cisplatin and vinorelbine &RTx
·  NECDAG Gateway Decision – CapVin in breast cancer
·  NECDAG Gateway Decision – Paclitaxel and carboplatin in ovarian cancer
·  NETAG Decision summary - Amifampridine phosphate (Firdapse®) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS)
·  NETAG Decision summary - OmniPod® continuous subcutaneous insulin infusion pump system / e-mail sent 21/11/11
e-mail sent 21/11/11
e-mail sent 21/11/11
e-mail sent 21/11/11
e-mail sent 12/12/11
e-mail sent 12/12/11
e-mail sent 12/12/11
e-mail sent 12/12/11
e-mail sent 12/12/11
e-mail sent 12/12/11
e-mail sent 12/12/11
e-mail sent 5/12/11
e-mail sent 5/12/11
12. / APC Guidelines and Statements for review
·  None to review
13. / Chairman’s action
·  None
14. / Any other business
15. / Date and time of next meeting:
Tuesday 13th March 2012.
Room 2 and 3 ,Northumbria House, Unit 7/8 Silver Fox Way, Cobalt Business Park, North Tyneside.
The meeting will start at 12:30pm

Page 1 of 2